Permira Advisers LLP completed the acquisition of Ergomed plc for £703.1 million. Ergomed is a differentiated Pharmacovigilance (PV) and contract research organization (CRO) platform with a strong track record in the complex oncology and rare diseases spaces and a reputation for high-quality, bespoke, customer centric delivery across its services. Ergomed operates in growing markets which benefit from increasing complexity, regulatory requirements, and outsourcing rates. Ergomed has strengthe...